AstraZeneca plc’s (AZN) “Reduce” Rating Reaffirmed at HSBC Holdings plc
HSBC Holdings plc reaffirmed their reduce rating on shares of AstraZeneca plc (LON:AZN) in a research report sent to investors on Monday. They currently have a GBX 4,100 ($52.95) price target on the biopharmaceutical company’s stock.
Other equities analysts have also recently issued reports about the stock. Berenberg Bank lifted their target price on shares of AstraZeneca plc from GBX 5,670 ($73.23) to GBX 5,850 ($75.55) and gave the company a buy rating in a report on Wednesday, May 17th. Liberum Capital reaffirmed a buy rating and issued a GBX 5,500 ($71.03) target price on shares of AstraZeneca plc in a report on Tuesday, May 23rd. UBS AG set a GBX 5,150 ($66.51) target price on shares of AstraZeneca plc and gave the company a neutral rating in a report on Tuesday, June 27th. J P Morgan Chase & Co reaffirmed a neutral rating on shares of AstraZeneca plc in a report on Thursday, July 13th. Finally, Credit Suisse Group cut their target price on shares of AstraZeneca plc from GBX 5,000 ($64.57) to GBX 4,700 ($60.70) and set a neutral rating on the stock in a report on Friday, July 28th. Three investment analysts have rated the stock with a sell rating, nine have given a hold rating and ten have assigned a buy rating to the stock. The company currently has an average rating of Hold and an average price target of GBX 4,963.82 ($64.11).
Shares of AstraZeneca plc (LON:AZN) opened at 4900.50 on Monday. The stock has a 50 day moving average of GBX 4,571.40 and a 200 day moving average of GBX 4,878.32. The stock’s market capitalization is GBX 62.04 billion. AstraZeneca plc has a 12-month low of GBX 3,996.00 and a 12-month high of GBX 5,520.00.
AstraZeneca plc (LON:AZN) last announced its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $1.86 EPS for the quarter, beating analysts’ consensus estimates of $0.85 by $1.01. AstraZeneca plc had a net margin of 8.83% and a return on equity of 14.36%. Equities research analysts anticipate that AstraZeneca plc will post $3.75 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This news story was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/09/12/astrazeneca-plcs-azn-reduce-rating-reaffirmed-at-hsbc-holdings-plc.html.
The business also recently disclosed a dividend, which was paid on Monday, September 11th. Stockholders of record on Thursday, August 10th were paid a dividend of GBX 68.90 ($0.89) per share. This represents a dividend yield of 1.35%. The ex-dividend date was Thursday, August 10th.
In other news, insider Nazneen Rahman bought 39 shares of the firm’s stock in a transaction dated Thursday, July 27th. The stock was acquired at an average price of GBX 4,370 ($56.44) per share, for a total transaction of £1,704.30 ($2,201.08).
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.